中西医结合治疗肝纤维化研究进展与思考*

doi:10.3969/j.issn.1672-5069.2025.06.002

摘要/Abstract

Key words: Liver fibrosis, Chinese traditional medicine, Therapy, Progress

李思思, 姜艳贞, 付兆媛. 中西医结合治疗肝纤维化研究进展与思考^*[J]. 实用肝脏病杂志, 2025, 28(6): 805-808.

Li Sisi, Jiang Yanzhen, Fu Zhaoyuan. Chinese traditional and western medicine in the treatment of liver fibrosis:current state of the art, controversies, and perspectives[J]. Journal of Practical Hepatology, 2025, 28(6): 805-808.

参考文献

[1] Parola M, Pinzani M. Liver fibrosis:pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med,2019,65:37-55.
[2] 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版).中华肝脏病杂志,2019,27(7):494-504.
[3] Khanam A, Saleeb PG, Kottilil S. Pathophysiology and treatment options for hepatic fibrosis:can it be completely cured? Cells,2021,10(5):1097.
[4] Zhu Y, Chai Y, Xiao G, et al. Astragalus and its formulas as a therapeutic option for fibrotic diseases: pharmacology and mechanisms. Front Pharmacol,2022,13:1040350.
[5] Sun X, Zheng Y, Tian Y, et al. Astragalus polysaccharide alleviates alcoholic-induced hepatic fibrosis by inhibiting polymerase I and transcript release factor and the TLR4/JNK/NF-κB/MyD88 pathway. JEP,2023,314:116662.
[6] Yang Z, Qi J, Ping D, et al. Salvia miltiorrhiza in thorax and abdomainal organ fibrosis:a review of its pharmacology. Front Pharmacol,2022,13:999604.
[7] Ying Q, Teng Y, Zhang J, et al. Therapeuticeffect of tanshinone IIA on liver fibrosis and the possible mechanism: apreclinical meta-analysis. Evid Based Comple Alt,2019,2019:7514046.
[8] Li Q, Huang D, Liao W, et al. Tanshinone IIA regulates CCl₄ induced liver fibrosis in C57BL/6J mice via the PI3K/Akt and Nrf2/HO-1 signaling pathways. J Biochem MolToxic,2024,38(2):e23648.
[9] 施光峰,李谦,翁心华,等. 苦参素对大鼠纤维化肝脏金属蛋白酶-1和α-平滑肌肌动蛋白表达的影响.中华肝脏病杂志,2004,12(1):56-56.
[10] Song LY, Ma YT, Fang WJ, et al. Inhibitory effects of oxymatrine on hepatic stellate cells activation through TGF-β/miR-195/Smad signaling pathway. BMCComplem Altern Med,2019,19:1-9.
[11] Sun S, Zhang G, Lyu S, et al. Potential mechanisms of traditionalChinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota. Front Microbiol,2024,15:1407991.
[12] He X, Liang J, Li X,et al. Dahuang zhechong pill ameliorates hepatic fibrosis by regulating gut microbiota and metabolites. J Ethnopharmacol,2024,321:117402.
[13] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells,2020,9(4):875.
[14] Ye Z, Huang Q, She Y, et al. A meritorious integrated medical regimen for hepatic fibrosis and its complications via thesystematic review and meta-analysis for dahuang zhechong pill-based therapy. Front Med (Lausanne),2022,9:920062.
[15] Cai FF, Wu R, Song YN,et al. Yinchenhaodecoction alleviates liver fibrosis by regulating bile acid metabolism and TGF-β/Smad/ERK signalling pathway. Sci Rep,2018,8(1):15367.
[16] Zhang H, Wang X, Hu P, et al. Serum metabolomic characterization of liver fibrosis in rats and anti-fibrotic effects ofyin-chen-hao-tang. Mole,2016,21(1):126.
[17] Cai FF, Bian YQ, Wu R, et al. Yinchenhao decoction suppressesrat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis. Biomed Pharmacother,114:108863.
[18] Tang DD, Zhang Q, Duan H, et al. Polydatin:a critical promising natural agent for liver protection via antioxidative stress. Oxid Med Cell Longev,2022(2):9218738.
[19] Cheng K, Niu JY, Zheng XT, et al. Aflatoxin-B1-exposure-induced hepatic injury could be alleviated by polydatin through reducing oxidative stress, inhibiting inflammation and improving mitophagy. Toxics,2023,11(4):309.
[20] Zhou Y, Wu R, Cai FF, et al. Xiaoyaosan decoction alleviated rat liver fibrosis via the TGFβ/Smad and Akt/FoxO3 signaling pathways based on network pharmacology analysis. JEP,2021,264:113021.
[21] Zhou Y, Wu R, Cai FF, et al. Development of a novel anti-liver fibrosis formula with luteolin, licochalcone a, aloe-emodin and acacetin by network pharmacology and transcriptomics analysis.Pharm Biol,2021,59(1):1594-1606.
[22] 陶庆,王晓柠,慕永平,等. 四氯化碳诱导大鼠肝纤维化脂质过氧化相关蛋白表达的动态变化及一贯煎的干预效应.中华肝脏病杂志,2012,20(2):116-121.
[23] Xu Y, Xu W, Liu W, et al. Yiguanjian decoction inhibits macrophage M1 polarization and attenuates hepatic fibrosis induced by CCl4/2-AAF. Pharm Biol,2021,59(1):1150-1160.
[24] 范晔,郝坤艳,李平,等. 扶正化瘀组方治疗乙型肝炎肝纤维化或肝硬化疗效的荟萃分析.中华肝脏病杂志,2024,32(12):1141-1152.
[25] 王林,卢玮,高玉华,等. 安络化纤丸对肝纤维化大鼠肝组织基质金属蛋白酶及其抑制物表达的影响.中华肝脏病杂志,2019,27(4):267-273.
[26] Wang F, Gan J, Li R, et al. Naringin fromganshuang granule inhibits inflammatory to relieve liver fibrosis through TGF-β-Smad signaling pathway. PLoS One,19(6):e0304185.
[27] You CR, Lee SW, Jang JW, et al. Update on hepatitis B virus infection. World J Gastroenterol,2014,20(37):13293-305.
[28] 赵鸿,斯崇文,魏来,等. 聚乙二醇化干扰素α-2b与干扰素α-2b治疗e抗原阳性慢性乙型肝炎的疗效和安全性的随机对照多中心研究.中华肝脏病杂志,2006,14(5):323-326.
[29] Gu L, Zhu Y, Lee M, et al. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. PNAS,2023,120(19): e2300706120.
[30] 曹伟,闫蕾,王玮,等. 辛伐他汀抑制肝星状细胞活化及其对腺苷酸活化蛋白激酶活性的影响.中华肝脏病杂志,2012,20(4):304-309.
[31] Kitsugi K, Noritake H, Matsumoto M, et al. Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway. Biochim Biophys Acta Mol Basis Dis,2023,1869(7):166750.
[32] Ibrahim SA, Mohamed MZ, El-Tahawy NF, et al. Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats. Can J Physiol Pharm,2021,99(3):313-320.
[33] 贾晋斌,刘燕,陈尉华,等. 吡格列酮对转化生长因子β诱导的大鼠肝星状细胞的影响.中华肝脏病杂志,2007,15(3):192-195.
[34] Zhang C, Liu XQ, Sun HN, et al. Octreotide attenuates hepatic fibrosis and hepatic stellate cells proliferation and activation by inhibiting Wnt/β-catenin signaling pathway, c-Myc and cyclin D1. Int Immunopharmacol,2018,63:183-190.
[35] Sun Y, Liu B, Xie J, et al. Aspirin attenuates liver fibrosis by suppressing TGF-β1/Smad signaling. Mol Med Rep,2022,25(5):181.
[36] Wang T, Fu X, Jin T, et al. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.EBioMedicine,2019,45:168-180.
[37] Karimi J,Mohammadalipour A,Sheikh N,et al.Protective effects of combined losartan and nilotinib on carbon tetrachloride (CCl (4))-induced liver fibrosis in rats.Drug Chem Toxicol,2020,43(5):468-478.
[38] Hassan MH,Ghobara MM.Antifibrotic effect of meloxicam in rat liver: role of nuclear factor kappa b,proinflammatory cytokines,and oxidative stress.N-S Arch Pharmacol,2016,389(9):971-983.
[39] 刘梅,郑瑞丹,窦爱霞,等. 多烯磷脂酰胆碱对人肝星状细胞增殖和氧应激及转化生长因子β1表达的影响.中华肝脏病杂志,2007,15(12):945-946.
[40] Wu M, Zhou Y, Qin SL, et al. Fuzheng huayu capsule attenuates hepatic fibrosis by inhibiting activation of hepatic stellate cells. Evid Based Complement Alternat Med,2020(1):3468791.
[41] Zhang T, Yang Y, Wang B,et al. Meta-analysis of influences of biejiajian pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: protocol of systematic review and meta-analysis. Medicine (Baltimore),2019,98(51):e18458.
[42] 万贵香,李忠廉,赵亚博,等.恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者疗效研究.实用肝脏病杂志,2024,27(2):234-237.

中西医结合治疗肝纤维化研究进展与思考^*

Chinese traditional and western medicine in the treatment of liver fibrosis:current state of the art, controversies, and perspectives

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姚羽, 宁波. 肝硬化门静脉血栓形成机制、自发性再通和抗凝治疗研究进展^*[J]. 实用肝脏病杂志, 2025, 28(6): 801-804.
[2]	杨思琪, 陈佳炜, 李少涵, 郭雪, 黄琛, 陈慧婷, 周永健. Coprococcus eutactus改善代谢相关性脂肪性肝病小鼠肝组织脂肪代谢实验研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 813-817.
[3]	华琪, 刘琼, 陈琦. 艾米替诺福韦治疗经恩替卡韦治疗的低病毒血症的慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 818-821.
[4]	蒋婵娟, 邵靖渊, 徐林. 艾尔巴韦/格拉瑞韦治疗慢性肾病合并慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 822-825.
[5]	王超杰, 谢群, 姜海, 周宝勤, 杨亮. 3D方案治疗初始治疗的基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 826-829.
[6]	李卉, 陶娅, 胥勋梅, 王金帆. 利拉鲁肽治疗NAFLD合并T2DM患者疗效及其对外周血单个核细胞NLRP3、Caspase-1和ASC水平的影响^*[J]. 实用肝脏病杂志, 2025, 28(6): 830-833.
[7]	郑慧慧, 王玉蓉, 徐婷. 血脂康联合阿托伐他汀治疗非酒精性脂肪性肝病合并高脂血症患者效果研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 834-837.
[8]	王美玲, 李洁, 刘娟, 孙婷婷. 司美格鲁肽联合非诺贝特治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 838-841.
[9]	高海娜, 梁盼, 高琳辉, 朱立影, 宋媛, 李印肖, 刘阳. 艾塞那肽联合二甲双胍治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 842-845.
[10]	陈晓玲, 张盼盼, 付玉芳, 王静. 司美格鲁肽联合化痰祛瘀通络方治疗NAFLD合并T2DM患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 846-849.
[11]	田巍巍, 孙佳琦, 陈恳, 黄亚彬, 李锋, 冯海娟. 标准免疫抑制疗法联合甘草酸二铵治疗自身免疫性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 854-857.
[12]	黄晓黎, 沈杰. 恩替卡韦联合红外肝病治疗仪治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 878-881.
[13]	陈杉杉, 司晓闯, 朱家宝, 谢淑慧, 吴静, 吴彬彬, 徐艳青, 梁燕楼, 王子弦, 孙亚楠. 多种无创诊断指标评估原发性胆汁性胆管炎患者肝硬化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 886-889.
[14]	杨兰, 许诗杰, 包华鑫. 肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 890-893.
[15]	李建林, 李娅, 郑秋然, 王燕. ¹²⁵I放射性粒子植入联合TACE治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 894-897.